Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1995 Aug:7 Suppl 1:S45-7.

Combination therapy with mucosal protective agent for the eradication of Helicobacter pylori

Affiliations
  • PMID: 8574735
Clinical Trial

Combination therapy with mucosal protective agent for the eradication of Helicobacter pylori

Y Fukuda et al. Eur J Gastroenterol Hepatol. 1995 Aug.

Abstract

Objective: To investigate the effect of plaunotol in combination with proton-pump inhibitors on Helicobacter pylori eradication in patients with gastric ulcer.

Patients and methods: We studied 65 H. pylori-positive gastric ulcer patients. They were randomly assigned to five treatment groups: omeprazole (group I, n = 8), lansoprazole (group II, n = 13), lansoprazole+plaunotol (group III, n = 12), lansoprazole+clarithromycin (group IV, n = 16) and lansoprazole+plaunotol+clarithromycin (group V, n = 16). Ulcer status was diagnosed by endoscopy and H. pylori status by culture, histology, a urease test and a urea breath test at baseline, and after 8 and 12 weeks. The clearance and eradication rates were compared in each group.

Results: The healing rates in groups I-V were 100, 92, 100, 100 and 100%, respectively; clearance rates were 0, 23, 42, 50 and 75%, respectively; and eradication rates were 0, 0, 8, 38 and 69%, respectively.

Conclusion: Combination therapy with plaunotol is efficacious for the eradication of H. pylori in gastric ulcer patients.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources